Physostigmine in Alzheimer's disease: effects on cognitive functioning, cerebral glucose metabolism analyzed by positron emission tomography and cerebral blood flow analyzed by single photon emission tomography
Tune L, Brandt J, Frost J, Harris G, Mayberg H, Steele C, Burns A, Sapp J, Folstein M, Wagner H, Pearlson G. Physostigmine in Alzheimer's disease: effects on cognitive functioning, cerebral glucose metabolism analyzed by positron emission tomography and cerebral blood flow analyzed by single photon emission tomography. Acta Psychiatrica Scandinavica. Supplementum 1991, 83: 61-65. PMID: 1897377, DOI: 10.1111/j.1600-0447.1991.tb03111.x.Peer-Reviewed Original ResearchMeSH KeywordsAgedAlzheimer DiseaseAmphetaminesBlood GlucoseBrainCerebrovascular CirculationDeoxyglucoseDose-Response Relationship, DrugDrug Administration ScheduleFemaleFluorodeoxyglucose F18HumansMaleMiddle AgedNeuropsychological TestsPhysostigminePilot ProjectsTomography, Emission-ComputedTomography, Emission-Computed, Single-PhotonConceptsCerebral glucose metabolismCerebral blood flowSingle photon emission tomographyPhoton emission tomographyPositron emission tomographyBlood flowEmission tomographyGlucose metabolismAlzheimer's diseaseRegional cerebral glucose metabolismSignificant clinical improvementCognitive functioningClinical improvementMost patientsIntravenous administrationPatientsDiseasePhysostigmineTomographyBrain activityPreliminary findingsMetabolismPronounced improvementPathophysiologyIllness